Table 2.
Ventilator and the ECMO parameters, indicators of infection, and renal function.
| D1 | D2 | D3 | D5 | D7 | D8 | D9 | D12 | D17 | |
|---|---|---|---|---|---|---|---|---|---|
| FiO2 | 100% | 60% | 60% | 100% | 100% | 40% | 40% | 35% | 35% |
| PEEP (cmH2O) | 10–8 | 8 | 8–5 | 8–10 | 8–10 | 5 | 5 | 5 | 3–5 |
| Pplat | 18 | 15 | 16 | 18 | 18 | 15 | 14 | 12 | 8 |
| CL (ml/mmHg) | 35 | 38 | 42 | 33 | 38 | 41 | 49 | 56 | 65 |
| Vt (ml) | 300–400 | 400–450 | 400–450 | 300 | 300–400 | 300–400 | 400–45– | 400–500 | 400–500 |
| PCO2 (mmHg) | 30 | 32 | 42 | 42 | 42 | 55 | 36 | 38 | 34 |
| PO2 (mmHg) | 71 | 97 | 167 | 59 | 439 | 96 | 102 | 71 | 80 |
| P/F ratio (mmHg) | 71 | 161 | 228 | 59 | 439 | 192 | 240 | 177.5 | 228.6 |
| ECMOration rate (revolutions/min) | – | – | – | 3,000 | 3,200 | 3,200 | 3,200 | 2,200 | – |
| ECMO flux (3 L/min) | – | – | – | 3.3 | 3.3 | 3.3 | 3.3 | 1.4 | – |
| ECMO FiO2 | – | – | – | 100% | 100% | 100% | 100% | 40% | – |
| Dosage of vasoactive drugs | NE 20 ug/min | NE 15 ug/min | NE 15 ug/min | NE 30 ug/min pavee DFA 55 ug/min | NE 15 ug/min pavee DFA 30 ug/min | NE 15 ug/min pavee DFA 30 ug/min | NE 15 ug/min pavee DFA 30 ug/min | – | – |
| Antibiotics | Meropenem and ganciclovir | Meropenem and ganciclovir | Meropenem and ganciclovir | Meropenem and ganciclovir | Meropenem, ganciclovir and azithromycin | Meropenem, ganciclovir and azithromycin | Meropenem, ganciclovir and azithromycin | Meropenem and doxycycline | Doxycycline |
| W.B.C (mm3) | 3,830 | 6,090 | 10,950 | 13,290 | 6,270 | 7,820 | 7,650 | 5,760 | 2,770 |
| PCT (ng/ml) | 6.51 | 60.1 | 58.7 | 35.9 | 16 | 9.23 | 5.2 | 1.38 | 0.84 |
| Cr (umol/L) | 178 | 243 | 180 | 242 | 180 | 139 | 199 | 171 | 209 |
| Urine volume (ml) | 1,450 | 2,060 | 1,400 | 300 | 70 | 50 | 30 | 40 | 1,700 |
FiO2, fraction of inspired oxygen; PEEP, positive end-expiratory pressure; VT, tidal volume; Pplat, platform pressure; CL, lung compliance; pCO2, partial pressure of carbon dioxide; pO2, partial pressure of oxygen; WBC, white blood cell; PCT, procalcitonin.